MicroCloud Hologram Inc. (NASDAQ: HOLO), ("HOLO" or the "Company"), a technology service provider, developed a technology based on quantum key distribution protocol and quantum random number ...
The Phase II trial enrolled 129 participants, of whom 94% had relapsing remitting multiple sclerosis, and 6% had secondary ...
Have you ever wished to drive microscopic matter along an arbitrarily tailored trajectory instead of just a circle? That's ...
Scientists have unveiled a breakthrough imaging method that can capture the hidden details of events unfolding in trillionths ...
A novel imaging method captures ultrafast events with unprecedented detail by combining laser encoding and AI reconstruction. Researchers have introduced a new imaging method that reveals far more ...
Researchers have developed a new imaging technique that captures more information about ultrafast processes in the ...
FB301 was safe and well tolerated in healthy female subjects, with all primary and secondary endpoints metClinically meaningful microbiome ...
All 4 T1D participants receiving SAB-142 showed C-peptide preservation with 3 of the 4 participants showing a super responder ...
Enrollment concludes with just over 60 patients participating across seven clinical sites located throughout the United States VANCOUVER, Washington, April 21, 2026 (GLOBE NEWSWIRE) -- CytoDyn Inc.
Researchers have developed a new imaging technique that captures more information about ultrafast processes in the microscopic world than was previously possible.
Researchers reported favorable safety and tolerability for CS1 after 12 months of treatment in patients with pulmonary arterial hypertension.
ULIXACALTAMIDE maintained response in essential tremor in a Phase III randomized withdrawal study at AAN 2026. The topline ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results